Nuo TherapeuticsAURX 33 Market Cap is $48.89 Mil as of Jun. 29, 2026. GuruFocus rates AURX with a GF Score™ of 33/100 and a GF Value™ of $4.23 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,428 Biotechnology companies, Nuo Therapeutics ranks worse than 63.17% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Nuo Therapeutics's share price for the quarter that ended in Mar. 2026 was $1.45. Nuo Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 48.29 Mil. Therefore, Nuo Therapeutics's market cap for the quarter that ended in Mar. 2026 was $70.02 Mil.
Nuo Therapeutics's quarterly market cap
declined
from Sep. 2025 ($97.68 Mil) to Dec. 2025 ($94.91 Mil) and
declined
from Dec. 2025 ($94.91 Mil) to Mar. 2026 ($70.02 Mil).
Nuo Therapeutics's annual market cap
increased
from Dec. 2023 ($24.33 Mil) to Dec. 2024 ($65.54 Mil) and
increased
from Dec. 2024 ($65.54 Mil) to Dec. 2025 ($94.91 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Nuo Therapeutics's Enterprise Value for Today is $49.73 Mil.
Nuo Therapeutics (OTCPK:AURX) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Nuo Therapeutics Market Cap Related Terms
Nuo Therapeutics Market Cap Historical Data
* Premium members only.
The historical data trend for Nuo Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Nuo Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nuo Therapeutics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nuo Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Nuo Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Nuo Therapeutics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nuo Therapeutics (AURX) has a Market Cap of $48.89 Mil as of Jun. 29, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Nuo Therapeutics and its competitors. According to the industry distribution chart, Nuo Therapeutics ranks #902 out of 1428 companies in the Biotechnology industry, placing it in the top 63.2%.
Is Nuo Therapeutics' Market Cap too high?
Nuo Therapeutics' current Market Cap is $48.89 Mil. The Biotechnology industry median Market Cap is 114.03. Nuo Therapeutics' value of $48.89 Mil is 57.1% below this industry median. Based on the distribution chart, Nuo Therapeutics ranks #902 out of 1428 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Nuo Therapeutics has a GF Score™ of 33/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nuo Therapeutics' Market Cap compare to PDSB and LTRN?
According to the Biotechnology industry distribution chart, Nuo Therapeutics ranks #902 out of 1428 companies for Market Cap. This places Nuo Therapeutics in the lower half of its industry. The industry median Market Cap is 114.03. Nuo Therapeutics' value of $48.89 Mil is 57.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 114.03, based on 1,428 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nuo Therapeutics's current Market Cap of $48.89 Mil is 57.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Nuo Therapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 114.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nuo Therapeutics's current Market Cap is $48.89 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nuo Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Nuo Therapeutics (AURX) is currently considered Possible Value Trap. The stock's GF Value™ is $4.23, compared to a current price of $1.01 — trading 76.1% below its estimated fair value. The current Market Cap is $48.89 Mil and 57.1% below the Biotechnology industry median of 114.03. Nuo Therapeutics' overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Nuo Therapeutics (AURX), the current Market Cap is $48.89 Mil as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nuo Therapeutics (AURX) Overvalued in 2026?
Based on GuruFocus' analysis, Nuo Therapeutics stock appears to be undervalued.
The current stock price of $1.01 is trading 76.1% below its estimated GF Value™ of $4.23.
GuruFocus considers Nuo Therapeutics to be Possible Value Trap.
Key valuation signals for AURX:
Market Cap: $48.89 Mil
GF Value™: $4.23 vs. price of $1.01 (76.1% below fair value)
Industry Position: 57.1% below the Biotechnology median (#902 of 1428)
No single metric tells the full story. See the AURX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nuo Therapeutics Inc is a commercial-stage medical device company engaged in developing and marketing products for chronic wound care. The company operates as a single segment focused on regenerative therapies that utilize autologous (patient-derived) biological materials to promote natural healing. Its primary commercial product is the Aurix System, a point-of-care technology that produces platelet-rich plasma (PRP) therapy from a patient's own blood for use in the treatment of chronic wounds.
33GF Score
Get the complete analysis for AURX
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AURX has been successfully added to your 
